Clinicopathologic Correlation: Differentiating Between Localized Lichen Myxedematosus and Scleromyxedema

Main Article Content

Kamran K. Harper, MD
University of Pittsburgh Department of Dermatology/UPMC

Lauryn M. Falcone, MD, PhD
University of Pittsburgh Department of Dermatology/UPMC

Kevin T. Savage, MD
University of Pittsburgh Department of Dermatology/UPMC

Alaina J. James, MD, PhD
University of Pittsburgh Department of Dermatology/UPMC

Keywords

scleromyxedema, lichen myxedematosus, cutaneous mucinosis, Clinicopathologic correlation

References

1. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44(2):273-281. doi:10.1067/mjd.2001.111630

2. Rongioletti F, Merlo G, Carli C, et al. Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases. J Am Acad Dermatol. 2016;74(6):1194-1200. doi:10.1016/j.jaad.2015.12.021

3. Fleming KE, Virmani D, Sutton E, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol. 2012;39(5):508-517. doi:10.1111/j.1600-0560.2012.01882.x

4. Knobler R, Moinzadeh P, Hunzelmann N, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology. 2017;31(10):1581-1594. doi:10.1111/jdv.14466

Article Sidebar

PDF
Published
Jul 7, 2022
DOI https://doi.org/10.25251/skin.6.4.15

Article Details

How to Cite
[1]
Harper, K., Falcone, L., Savage, K. and James, A. 2022. Clinicopathologic Correlation: Differentiating Between Localized Lichen Myxedematosus and Scleromyxedema . SKIN The Journal of Cutaneous Medicine. 6, 4 (Jul. 2022), 341–342. DOI:https://doi.org/10.25251/skin.6.4.15.
Issue
Vol. 6 No. 4 (2022): July 2022 Issue
Section
Short Communications
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.